Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Fein

Showing results (41-50 of 49) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 49 results.
Antimicrobial Agents and Chemotherapy|March 24, 2010
Combined antibacterial and anti-inflammatory activity of a cationic disubstituted dexamethasone-spermine conjugateRobert Bucki, Katarzyna Leszczynska, Fitzroy J Byfield, et al.
JCO Global Oncology|March 24, 2022
Biosimilar Versus Originator Pegfilgrastim for Preventing Chemotherapy-Induced Neutropenia: A Phase III Randomized, Multicenter, Evaluator-Blinded, Noninferiority StudyRuben D Kowalyszyn, Luis E Fein, Martin E Richardet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2000
Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study GroupM Kaufmann, E Bajetta, L Y Dirix, et al.
Clinical Breast Cancer|April 24, 2002
Exemestane improves survival in metastatic breast cancer: results of a phase III randomized studyM Kaufmann, E Bajetta, L Y Dirix, et al.
Breast Cancer Research and Treatment|May 11, 2010
Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanesGabriel N Hortobagyi, Henry L Gomez, Rubi K Li, et al.
The New England Journal of Medicine|May 10, 2023
Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell CarcinomaToni K Choueiri, Thomas Powles, Laurence Albiges, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 31, 2007
Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatmentEva S Thomas, Henry L Gomez, Rubi K Li, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 19, 2010
Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancerA D Seidman, A Brufsky, R H Ansari, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 13, 2022
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancerC E Geyer, J E Garber, R D Gelber, et al.
Pageof 5

Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Antimicrobial Agents and Chemotherapy|March 24, 2010
Combined antibacterial and anti-inflammatory activity of a cationic disubstituted dexamethasone-spermine conjugateRobert Bucki, Katarzyna Leszczynska, Fitzroy J Byfield, et al.
JCO Global Oncology|March 24, 2022
Biosimilar Versus Originator Pegfilgrastim for Preventing Chemotherapy-Induced Neutropenia: A Phase III Randomized, Multicenter, Evaluator-Blinded, Noninferiority StudyRuben D Kowalyszyn, Luis E Fein, Martin E Richardet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2000
Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study GroupM Kaufmann, E Bajetta, L Y Dirix, et al.
Clinical Breast Cancer|April 24, 2002
Exemestane improves survival in metastatic breast cancer: results of a phase III randomized studyM Kaufmann, E Bajetta, L Y Dirix, et al.
Breast Cancer Research and Treatment|May 11, 2010
Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanesGabriel N Hortobagyi, Henry L Gomez, Rubi K Li, et al.
The New England Journal of Medicine|May 10, 2023
Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell CarcinomaToni K Choueiri, Thomas Powles, Laurence Albiges, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 31, 2007
Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatmentEva S Thomas, Henry L Gomez, Rubi K Li, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 19, 2010
Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancerA D Seidman, A Brufsky, R H Ansari, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 13, 2022
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancerC E Geyer, J E Garber, R D Gelber, et al.
Pageof 5